{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:42:58Z","timestamp":1791434578203,"version":"4.3.3"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Treatment and prophylaxis options for neonatal HIV are limited. This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Using maraviroc concentrations from neonates who received either a single dose or multiple doses of 8\u2009mg\/kg of maraviroc in the first 6 weeks of life, a population pharmacokinetic model was developed to determine the effects of age, sex, maternal efavirenz exposure and concomitant ARV therapy on maraviroc disposition. The final model was used in Monte Carlo simulations to generate expected exposures with recommended dosing regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 396 maraviroc concentrations, collected in the first 4 days of life, at 1 week, at 4 weeks and at 6 weeks, from 44 neonates were included in the analysis. After allometrically scaling for weight, age less than 4 days was associated with a 44% decreased apparent clearance compared with participants 7 days to 6 weeks of life. There were no differences identified in apparent clearance or volume of distribution from ages 7 days to 6 weeks, sex, maternal efavirenz exposure or concomitant nevirapine therapy. Monte Carlo simulations with FDA-approved weight band dosing resulted in the majority of simulated patients (84.3%) achieving an average concentration of \u226575\u2009ng\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>While maraviroc apparent clearance is decreased in the first few days of life, the current FDA-approved maraviroc weight band dosing provides maraviroc exposures for neonates in the first 6 weeks of life, which were consistent with adult maraviroc exposure range. Maraviroc provides another antiretroviral treatment option for very young infants.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003665","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T18:00:52Z","timestamp":1660845652000},"page":"885-890","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life"],"prefix":"10.1097","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3801-6174","authenticated-orcid":false,"given":"Marlon","family":"Liyanage","sequence":"first","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Nikanjam","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"McFadyen","sequence":"additional","affiliation":[{"name":"Department of Pharmacometrics, Pfizer Global Research and Development, Sandwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoli","family":"Vourvahis","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Pfizer Global Research and Development, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Rogg","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Moye","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen G.","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Jean-Philippe","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Whitson","sequence":"additional","affiliation":[{"name":"Frontier Science Foundation, Amherst, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bradford","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund V.","family":"Capparelli","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA"},{"name":"Pediatrics Department, School of Medicine, University of California San Diego-Rady Children\u2019s Hospital San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8569-2293","authenticated-orcid":false,"given":"Brookie M.","family":"Best","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA"},{"name":"Pediatrics Department, School of Medicine, University of California San Diego-Rady Children\u2019s Hospital San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/QAD.0000000000000212","article-title":"Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011.","volume":"28","author":"Townsend","year":"2014","journal-title":"AIDS"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11904-018-0412-1","article-title":"CNS persistence of HIV-1 in children: the untapped reservoir.","volume":"15","author":"Chahroudi","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1097\/QAD.0b013e3283553638","article-title":"Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.","volume":"26","author":"Persaud","year":"2012","journal-title":"AIDS"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1086\/314854","article-title":"Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1.","volume":"180","author":"Semba","year":"1999","journal-title":"J Infect Dis"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/QAD.0000000000002762","article-title":"Pharmacokinetics and safety of maraviroc in neonates.","volume":"35","author":"Rosebush","year":"2021","journal-title":"AIDS"},{"issue":"suppl 1","key":"R12-20250614","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2125.2008.03134.x","article-title":"Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.","volume":"65","author":"Abel","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1310\/hct1103-125","article-title":"Efficacy and safety of maraviroc versus efavirenz, both with zidovudine\/lamivudine: 96-week results from the MERIT study.","volume":"11","author":"Sierra-Madero","year":"2010","journal-title":"HIV Clin Trials"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"e806","DOI":"10.1016\/j.ijid.2013.04.006","article-title":"Incidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapy.","volume":"17","author":"Bunupuradah","year":"2013","journal-title":"Int J Infect Dis"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","article-title":"Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.","volume":"331","author":"Connor","year":"1994","journal-title":"N Engl J Med"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM199104113241503","article-title":"A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.","volume":"324","author":"McKinney","year":"1991","journal-title":"N Engl J Med"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1086\/590160","article-title":"Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.","volume":"198","author":"Flys","year":"2008","journal-title":"J Infect Dis"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1089\/aid.2014.0370","article-title":"Nevirapine resistance in previously nevirapine-unexposed HIV-1-infected Kenyan infants initiating early antiretroviral therapy.","volume":"31","author":"Chohan","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"suppl 1","key":"R23-20250614","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2125.2008.03139.x","article-title":"A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.","volume":"65","author":"Chan","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0000000000001447","article-title":"Assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates.","volume":"75","author":"Cressey","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 1","key":"R25-20250614","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2008.03133.x","article-title":"Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.","volume":"65","author":"Abel","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1124\/dmd.112.048298","article-title":"Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc.","volume":"40","author":"Lu","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.103.054841","article-title":"Developmental expression of the major human hepatic CYP3A enzymes.","volume":"307","author":"Stevens","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"6 pt 1","key":"R28-20250614","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.1994.186","article-title":"Population pharmacokinetics of midazolam in neonates.","volume":"56","author":"Burtin","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-1033.1997.00625.x","article-title":"Expression of CYP3A in the human liver\u2013evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.","volume":"247","author":"Lacroix","year":"1997","journal-title":"Eur J Biochem"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2125.2009.03455.x","article-title":"Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.","volume":"68","author":"Weatherley","year":"2009","journal-title":"Br J Clin Pharmacol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:05:16Z","timestamp":1749945916000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003665","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,9]]}}}